We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc
RUBY

Delisted

RUBY was delisted on the 6th of March, 2023.

Back to rankings

57 hedge funds and large institutions have $1.11B invested in Rubius Therapeutics, Inc in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 13

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

4% more funds holding

Funds holding: 55 → 57 (+2)

28% less capital invested

Capital invested by funds: $1.54B → $1.11B (-$430M)

Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
1.27%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
12
Increased
20
Reduced
13
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.3M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$12M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$4M
4
Capital World Investors
Capital World Investors
California
+$3.1M
5
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$2.67M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$3.1M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$1.88M
3
GPCM
Granite Point Capital Management
Massachusetts
-$1.49M
4
MWNA
Marshall Wace North America
New York
-$1.41M
5
LCM
Laurion Capital Management
New York
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
51
Daiwa Securities Group
Japan
$10K +$11.6K +637 New
BFEC
52
Benjamin F. Edwards & Company
Missouri
$5K +$5.92K +325 New
Barclays
53
Barclays
United Kingdom
$3K -$79.4K -4,355 -96%
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$3K +$1.59K +87 +104%
IA
55
IFP Advisors
Florida
$2K -$12.4K -679 -87%
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$2K -$5.31K -291 -66%
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$627 -$237 -13 -25%
MWNA
58
Marshall Wace North America
New York
– -$1.41M -58,543 Closed
LCM
59
Laurion Capital Management
New York
– -$1.2M -50,000 Closed
BCM
60
BlueCrest Capital Management
Jersey
– -$667K -27,795 Closed
DIM
61
DC Investments Management
Virginia
– -$594K -24,742 Closed
Alyeska Investment Group
62
Alyeska Investment Group
Illinois
– -$382K -15,930 Closed
ZP
63
Zimmer Partners
New York
– -$360K -15,000 Closed
Citigroup
64
Citigroup
New York
– -$82K -3,400 Closed
UBS Group
65
UBS Group
Switzerland
– -$69K -2,868 Closed
SPIA
66
Steward Partners Investment Advisory
New York
– -$8K -350 Closed
CCA
67
Catalyst Capital Advisors
New York
– -$6K -250 Closed
1 2
3

RUBY Hedge Fund Activity: Q4 2018 in Review

57 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2018, worth a combined $1.11B — down 28% from $1.54B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RUBY positions and 10 closed out — a net gain of 2 holders — while 20 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $15.3M. The largest seller was Capital International Investors, cutting an estimated $3.1M.

  • 57 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2018, up from 55 in Q3 2018.
  • Funds reported $1.11B of Rubius Therapeutics, Inc stock for Q4 2018, down 28% quarter-over-quarter.
  • 12 funds opened new Rubius Therapeutics, Inc positions in Q4 2018 and 10 closed out, a net change of +2 holders.
  • The largest Rubius Therapeutics, Inc buyer in Q4 2018 was BlackRock, an estimated $15.3M added.
  • The largest Rubius Therapeutics, Inc seller in Q4 2018 was Capital International Investors, an estimated $3.1M sold.

Based on aggregated 13F filings for Q4 2018.